The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.
Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...
After hours: March 14 at 7:47:54 PM EDT Loading Chart for REGN ...
AN eye clinic is now open at the Metoreia Health Centre in the National Capital District.